LCTX logo

LCTX

Profile

Full Name

Lineage Cell Therapeutics, Inc.

Ticker Symbol

LCTX

Exchange

NYSE American

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

March 5, 1992

Indexes

Not included

Website

http://www.lineagecell.com

Employees

70

Key Details

Price

$0.43(-2.27%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$9.50M(+6.19% YoY)

Annual EPS

-$0.09(+25.00% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.43
LCTX price is $0.43

30-Day Relative Volume

0.52
LCTX 30-day relative volume is 0.52

Price Performance

Price Most recent change

-2.27%
LCTX price was down -2.27% on Apr 15, 2025

Price YTD change

-14%
LCTX price is down -14% since January 1st

Price 1-year change

-65.6%
LCTX price is down -65.6% year-on-year

Price 3-year change

-65.87%
LCTX price is down -65.87% over the past 3 years

Price Range

Price All-time high

$27.00
LCTX price is currently -98.41% below its historical high of $27.00

Price 3-year low

$0.37
LCTX price is currently +16.22% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$98.19M
LCTX market capitalization is $98.19 million

Market cap 3-year change

-54.08%
LCTX market capitalization is down -54.08% over the past 3 years

Market cap All-time high

$486.42M
LCTX market capitalization is currently -79.81% below its historical high of $486.42 million

Market cap sector rank

48.44%
LCTX market capitalization is higher than 48.44% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+20.98%
LCTX shares outstanding is up +20.98% year-on-year

Shares Outstanding 3-Year Change

+34.54%
LCTX shares outstanding is up +34.54% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.91
LCTX beta is 0.91

200-day SMA

$0.74
LCTX price is currently -41.59% below its 200-day simple moving average

50-day SMA

$0.55
LCTX price is currently -21.27% below its 50-day simple moving average

RSI

41.46
LCTX 14-day relative strength index is 41.46

Volume

0.52
LCTX 30-day relative volume is 0.52

ATR

$0.05
LCTX average true range is $0.05

10-day Historical Volatility

108.00%
LCTX 10-day historical volatility is 108.00%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$9.50M
LCTX annual revenue is $9.50 million

Revenue Analysts estimate

$11.28M
LCTX annual revenue is currently -15.77% lower than the consensus analysts' forecast

Revenue 1-year change

+6.19%
LCTX annual revenue is up +6.19% year-on-year

Revenue Sector rank

27.04%
LCTX annual revenue is higher than 27.04% of companies in Healthcare sector

EPS

EPS

-$0.09
LCTX annual earnings per share is -$0.09

EPS Analysts estimate

-$0.12
LCTX annual earnings per share is currently -23.73% lower than the consensus analysts' forecast

EPS 1-year change

+25%
LCTX annual earnings per share is up +25% year-on-year

EPS Sector rank

80.53%
LCTX annual earnings per share is higher than 80.53% of companies in Healthcare sector

Profit

Gross profit

$9.16M
LCTX annual gross profit is $9.16 million

Gross margin

96.48%
LCTX annual gross profit margin is 96.48%

Operating profit

-$21.48M
LCTX annual operating income is -$21.48 million

Operating margin

-226.11%
LCTX annual operating profit margin is -226.11%

Net income

-$18.61M
LCTX annual net profit is -$18.61 million

Net margin

-195.90%
LCTX annual net profit margin is -195.90%

Expenses

Total expenses

$30.98M
LCTX annual total expenses is $30.98 million

Operating expenses

$30.64M
LCTX annual total operating expenses is $30.64 million

Cost of goods sold

$334.00K
LCTX annual cost of goods sold is $334.00 thousand

Selling, general & administrative expenses

$18.17M
LCTX annual SGA is $18.17 million

Depreciation and amortization

$609.00K
LCTX annual depreciation & amortization is $609.00 thousand

Interest expense

-
LCTX annual interest expense value is unknown

Income tax

$0.00
LCTX annual income tax is $0.00

EBIT & EBITDA

EBIT

-$21.48M
LCTX annual earnings before interest & taxes is -$21.48 million

EBITDA

-$20.87M
LCTX annual EBITDA is -$20.87 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$113.22M
LCTX annual total assets is $113.22 million

Non current assets

$62.22M
LCTX annual long term assets is $62.22 million

Current assets

$51.00M
LCTX annual total current assets is $51.00 million

Cash and cash equivalents

$45.79M
LCTX annual cash & cash equivalents is $45.79 million

Accounts receivable

$638.00K
LCTX annual accounts receivable is $638.00 thousand

Inventory

-
LCTX annual inventory value is unknown

Liabilities

Total liabilities

$36.21M
LCTX annual total liabilities is $36.21 million

Long term liabilities

$22.23M
LCTX annual total long term liabilities is $22.23 million

Current liabilities

$13.98M
LCTX annual total current liabilities is $13.98 million

Accounts payable

$1.17M
LCTX annual accounts payable is $1.17 million

Debt

Total debt

$2.51M
LCTX annual total debt is $2.51 million

Total debt 1-year change

-14.84%
LCTX annual total debt is down -14.84% year-on-year

Long term debt

$1.36M
LCTX annual long term debt is $1.36 million

Short term debt

$1.15M
LCTX annual short term debt is $1.15 million

Equity & Capital

Shareholders equity

$78.38M
LCTX annual stockholders equity is $78.38 million

Book value

$78.38M
LCTX annual book value is $78.38 million

Retained earnings

-$403.46M
LCTX annual retained earnings is -$403.46 million

Working capital

$37.02M
LCTX annual working capital is $37.02 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$23.09M
LCTX annual cash flow from operations is -$23.09 million

Cash from operations 1-year change

+19.16%
LCTX annual cash flow from operations is up +19.16% year-on-year

Cash from investing

-$2.31M
LCTX annual cash flow from investing activities is -$2.31 million

Cash from investing 1-year change

-104.97%
LCTX annual cash flow from investing activities is down -104.97% year-on-year

Cash from financing

$35.86M
LCTX annual cash flow from financing activities is $35.86 million

Cash from financing 1-year change

+458.26%
LCTX annual cash flow from financing activities is up +458.26% year-on-year

CAPEX

CAPEX

$565.00K
LCTX annual capital expenditures is $565.00 thousand

CAPEX 1-year change

-16.17%
LCTX annual capital expenditures is down -16.17% year-on-year

Free Cash Flow

Free cash flow

-$23.66M
LCTX annual free cash flow is -$23.66 million

Free cash flow 1-year change

+19.09%
LCTX annual free cash flow is up +19.09% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

96.48%
LCTX annual gross profit margin is 96.48%

Operating margin

-226.11%
LCTX annual operating profit margin is -226.11%

Net margin

-195.90%
LCTX annual net profit margin is -195.90%

ROA & ROE

ROA

-17.37%
LCTX annual return on assets is -17.37%

ROE

-26.77%
LCTX annual return on equity is -26.77%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
LCTX price to earnings ratio value is unknown

PE ratio Sector rank

-
LCTX price to earnings ratio is unknown

PB Ratio

PB ratio

1.25
LCTX price to book ratio is 1.25

PB ratio Sector rank

49.71%
LCTX price to book ratio is higher than 49.71% of companies in Healthcare sector

PS Ratio

PS ratio

10.34
LCTX price to sales ratio is 10.34

PS ratio Sector rank

79.49%
LCTX price to sales ratio is higher than 79.49% of companies in Healthcare sector

Enterprise value

Enterprise value

$54.92M
LCTX enterprise value is $54.92 million

Enterprise value Sector rank

42.35%
LCTX enterprise value is higher than 42.35% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-2.63
LCTX EV/EBITDA is -2.63

EV/EBITDA Sector rank

28.2%
LCTX EV/EBITDA is higher than 28.2% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

3.65
LCTX annual current ratio is 3.65

Quick ratio

-
LCTX annual quick ratio value is unknown

Leverage

Debt to equity

0.00
LCTX annual debt to equity ratio is 0.00

Interest coverage ratio

-
LCTX annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

4
LCTX piotroski f-score is 4

Altman Z-Score

-3.51
LCTX altman z-score is -3.51

Analyst ratings

Recent major analysts updates

Mar 14, 25 B. Riley Securities
Buy
Mar 11, 25 HC Wainwright & Co.
Buy
Mar 11, 25 D. Boral Capital
Buy
Feb 11, 25 HC Wainwright & Co.
Buy
Feb 11, 25 D. Boral Capital
Buy
Jan 31, 25 HC Wainwright & Co.
Buy
Jan 10, 25 Maxim Group
Buy
Jan 3, 25 D. Boral Capital
Buy
Dec 4, 24 HC Wainwright & Co.
Buy
Nov 20, 24 D. Boral Capital
Buy

Institutional Ownership

Similar stocks

eXoZymes (EXOZ)
AIRS logo
AirSculpt Technologies (AIRS)
RPID logo
Rapid Micro Biosystems (RPID)
NAUT logo
Nautilus Biotechnology (NAUT)
XBIT logo
XBiotech (XBIT)
Invizyne Technologies (IZTC)
SNTI logo
Senti Biosciences (SNTI)
MGRM logo
Monogram Orthopaedics (MGRM)
IMUX logo
Immunic (IMUX)
  • What is the ticker symbol for Lineage Cell Therapeutics?
  • Does Lineage Cell Therapeutics pay dividends?
  • What sector is Lineage Cell Therapeutics in?
  • What industry is Lineage Cell Therapeutics in?
  • What country is Lineage Cell Therapeutics based in?
  • When did Lineage Cell Therapeutics go public?
  • Is Lineage Cell Therapeutics in the S&P 500?
  • Is Lineage Cell Therapeutics in the NASDAQ 100?
  • Is Lineage Cell Therapeutics in the Dow Jones?
  • When was Lineage Cell Therapeutics's last earnings report?
  • When does Lineage Cell Therapeutics report earnings?
  • Should I buy Lineage Cell Therapeutics stock now?

What is the ticker symbol for Lineage Cell Therapeutics?

The ticker symbol for Lineage Cell Therapeutics is NYSE American:LCTX

Does Lineage Cell Therapeutics pay dividends?

No, Lineage Cell Therapeutics does not pay dividends

What sector is Lineage Cell Therapeutics in?

Lineage Cell Therapeutics is in the Healthcare sector

What industry is Lineage Cell Therapeutics in?

Lineage Cell Therapeutics is in the Biotechnology industry

What country is Lineage Cell Therapeutics based in?

Lineage Cell Therapeutics is headquartered in United States

When did Lineage Cell Therapeutics go public?

Lineage Cell Therapeutics's initial public offering (IPO) was on March 5, 1992

Is Lineage Cell Therapeutics in the S&P 500?

No, Lineage Cell Therapeutics is not included in the S&P 500 index

Is Lineage Cell Therapeutics in the NASDAQ 100?

No, Lineage Cell Therapeutics is not included in the NASDAQ 100 index

Is Lineage Cell Therapeutics in the Dow Jones?

No, Lineage Cell Therapeutics is not included in the Dow Jones index

When was Lineage Cell Therapeutics's last earnings report?

Lineage Cell Therapeutics's most recent earnings report was on Mar 10, 2025

When does Lineage Cell Therapeutics report earnings?

The next expected earnings date for Lineage Cell Therapeutics is May 9, 2025

Should I buy Lineage Cell Therapeutics stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page